Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| (NYSE: RCUS) | Delayed: 19.10 -4.65 (19.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $23.75 | 52 Week High | $ | |||
| Open | $24.47 | 52 Week Low | $ | |||
| Day High | $24.47 | P/E | N/A | |||
| Day Low | $18.98 | EPS | $ | |||
| Volume | 4,650,943 | |||||
